<link rel='stylesheet' href='https//fonts.googleapis.com/css?family=Roboto:400,500,700,400italic|Material+Icons'>
Open Search
QLGN
Qualigen Therapeutics
$
()


  • Qualigen Therapeutics announces first patient dosed in Phase 1a trial of QN-302

    11/7/2023 - 08:43am
  • Qualigen Therapeutics announces poster highlighting Pan-RAS inhibitor platform

    10/23/2023 - 08:34am
  • Qualigen Therapeutics presents scientific data on QN-302 at AACR conference

    9/27/2023 - 08:35am
  • Qualigen Therapeutics partners with TD2 for Phase 1 development of QN-302

    8/17/2023 - 08:36am
  • Qualigen Therapeutics reports Q2 EPS (69c) vs ($1.12) last year

    8/15/2023 - 08:31am
  • Qualigen announces U.S. FDA IND clearance to initiate Phase 1 trial of QN-302

    8/1/2023 - 08:33am
  • Qualigen Therapeutics divests FastPack Diagnostics business

    7/24/2023 - 08:16am
  • One new option listing and eighteen option delistings on June 26th

    6/26/2023 - 08:30am
  • Qualigen Therapeutics files to sell common stock, warrants, no amount given

    6/13/2023 - 17:17pm
  • Qualigen Therapeutics announces poster highlighting Pan-RAS inhibitor platform

    6/5/2023 - 08:47am
  • Qualigen Therapeutics reports Q1 EPS (78c) vs ($1.22) last year

    5/16/2023 - 08:05am
  • Qualigen Therapeutics receives Nasdaq notice over delayed 10-K filing

    4/21/2023 - 17:47pm
  • Qualigen Therapeutics announces four poster presentations on QN-302

    4/18/2023 - 08:53am
  • Qualigen Therapeutics presents data on QN-247 at AACR meeting

    4/18/2023 - 07:34am
  • Qualigen Therapeutics granted patent for QN-302 by USPTO

    3/21/2023 - 08:39am
dynamic_feed Breaking News